Literature DB >> 21045690

Somatic mutations in cancer prognosis and prediction: lessons from TP53 and EGFR genes.

Magali Olivier1, Philippe Taniere.   

Abstract

PURPOSE OF REVIEW: We used two examples of genes, TP53 and EGFR, which are somatically altered by intragenic mutations in common cancer types to illustrate how somatic mutations have followed very different routes to clinical applications. RECENT
FINDINGS: TP53 somatic mutations are frequent in many cancers. Their prognostic and predictive values are currently assessed in several clinical trials and TP53 gene therapy is in use in China. Mutations in EGFR have been proved to be predictive of response to tyrosine kinase inhibitors, allowing for the licensing of gefitinib in lung adenocarcinomas carrying a mutated EGFR gene.
SUMMARY: With the accumulation of knowledge on the predictive and prognostic value of somatic mutations, and with recent advances in large-scale sequencing techniques and reduction in cost of sequencing, sequencing several genes in human tumors is on the verge of becoming routine clinical practice.

Entities:  

Mesh:

Year:  2011        PMID: 21045690     DOI: 10.1097/CCO.0b013e3283412dfa

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  21 in total

1.  Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression.

Authors:  Justin M Drake; Nicholas A Graham; Tanya Stoyanova; Amir Sedghi; Andrew S Goldstein; Houjian Cai; Daniel A Smith; Hong Zhang; Evangelia Komisopoulou; Jiaoti Huang; Thomas G Graeber; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

Review 2.  The Multifaceted Metabolism of Glioblastoma.

Authors:  Addison Quinones; Anne Le
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

Review 3.  Clonal evolution in cancer.

Authors:  Mel Greaves; Carlo C Maley
Journal:  Nature       Date:  2012-01-18       Impact factor: 49.962

4.  High frequency of temperature-sensitive mutants of p53 in glioblastoma.

Authors:  Jana Smardova; Kvetoslava Liskova; Barbora Ravcukova; Lenka Kubiczkova; Sabina Sevcikova; Jaroslav Michalek; Miluse Svitakova; Vaclav Vybihal; Leos Kren; Jan Smarda
Journal:  Pathol Oncol Res       Date:  2013-03-28       Impact factor: 3.201

5.  p53 mutations promote proteasomal activity.

Authors:  Moshe Oren; Eran Kotler
Journal:  Nat Cell Biol       Date:  2016-07-27       Impact factor: 28.824

6.  Unravelling mechanisms of p53-mediated tumour suppression.

Authors:  Kathryn T Bieging; Stephano Spano Mello; Laura D Attardi
Journal:  Nat Rev Cancer       Date:  2014-04-17       Impact factor: 60.716

7.  The Multifaceted Glioblastoma: From Genomic Alterations to Metabolic Adaptations.

Authors:  Addison Quinones; Anne Le
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  Aneuploidy and chromosomal instability in cancer: a jackpot to chaos.

Authors:  Maybelline Giam; Giulia Rancati
Journal:  Cell Div       Date:  2015-05-20       Impact factor: 5.130

9.  Network-based stratification analysis of 13 major cancer types using mutations in panels of cancer genes.

Authors:  Xue Zhong; Hushan Yang; Shuyang Zhao; Yu Shyr; Bingshan Li
Journal:  BMC Genomics       Date:  2015-06-11       Impact factor: 3.969

10.  p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.

Authors:  Lindi Chen; Deborah A Tweddle
Journal:  Front Oncol       Date:  2012-11-28       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.